MUC1 and cancer: Eleven months after the initiation of spIND therapy, the investigational human adenovirus serotype 5 (hAd5) vector-based cancer vaccines ETBX-051 (targeting carcinogenic embryonic antigen; CEA) and -061 (targeting mucin-1; MUC1) were added, and treatment with gemcitabine/nab-paclitaxel ceased.